JMP Securities lowered the firm’s price target on Prelude Therapeutics (PRLD) to $4 from $7 and keeps an Outperform rating on the shares after the company’s ASH presentation, where it presented a poster highlighting PRT2527, a CDK9 inhibitor, as a monotherapy and in combination with Brukinsa. JMP continues to believe Prelude shares represent an attractive investment opportunity with three assets advancing through the clinic, initial PRT3789 monotherapy demonstrating modest efficacy and a potential path forward as a combination agent, and a cash position of $153.6M, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health
- Prelude Therapeutics Shows Strong Q3 2024 Financial Results
- Prelude Therapeutics reports Q3 EPS (43c), consensus (47c)
- Prelude Therapeutics price target lowered to $1 from $3 at Barclays
- Prelude Therapeutics presents new data from Phase 1 trial of PRT3789